<DOC>
	<DOCNO>NCT01049633</DOCNO>
	<brief_summary>Type 1 diabetes autoimmune disease insulin-producing pancreatic beta cell destroy , result poor blood sugar control . The purpose study determine safety effectiveness islet transplantation , combine immunosuppressive medication medication support islet survival treat type 1 diabetes individual experience hypoglycemia unawareness severe hypoglycemic episode .</brief_summary>
	<brief_title>B-Lymphocyte Immunotherapy Islet Transplantation Initial Islet Graft Failure</brief_title>
	<detailed_description>Type 1 diabetes commonly treat administration insulin , either multiple insulin injection continuous supply insulin wearable pump . Insulin therapy allow long-term survival individual type 1 diabetes ; however , guarantee constant normal blood sugar control . Because , long-term type 1 diabetic survivor often develop vascular complication , diabetic retinopathy , eye disease cause poor vision blindness , diabetic nephropathy , kidney disease lead kidney failure . Some individual type 1 diabetes develop hypoglycemia unawareness , life-threatening condition easily treatable medication characterize reduced absent warning signal hypoglycemia . For individual , pancreas pancreatic islet transplantation possible treatment option . Insulin independence among islet transplant recipient tend decline time . New strategy aim promote engraftment transplant islet need improve clinical outcome associated procedure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>Enrolled clinical trial DAIT CIT05 ( NCT00468442 ) Islet graft failure : absent stimulate Cpeptide ( &lt; 0.3ng/mL ) response mixed meal tolerance test Untreated proliferative diabetic retinopathy Blood Pressure : systolic blood pressure &gt; 160mmHg diastolic blood pressure &gt; 100mmHg Measured glomerular filtration rate ( GFR ) use iohexol &lt; 80ml/min/1.73m^2 Strict vegetarian calculate GFR &lt; 70ml/min/1.73m^2 Presence history macroalbuminuria &gt; 300mg/g creatinine Presence history panelreactive antiHLA antibody background flow cytometry For female participant : Positive Pregnancy Test , presently breastfeed , unwillingness use effective contraceptive measure duration study 3 month discontinuation . For male participant : intent procreate duration study within 3 month discontinuation unwillingness use effective measure contraception . Oral contraceptive , Norplant , DepoProvera barrier device spermicide acceptable contraceptive method ; condom use alone acceptable . Active infection include hepatitis B , hepatitis C , HIV , TB determine positive skin test clinical presentation , treatment suspect TB . Positive test acceptable associate history previous vaccination absence sign active infection . Positive test otherwise acceptable , even absence active infection time evaluation . Negative screen EpsteinBarr Virus ( EBV ) IgG determination Invasive aspergillus , histoplasmosis , coccidiomycosis infection within one year prior study enrollment Any history malignancy except completely resect squamous basal cell carcinoma skin Known active alcohol substance abuse Anemia ( Hgb &lt; 11 g/dL ) , neutropenia ( &lt; 1,500/µL ) , thrombocytopenia ( platelet &lt; 100,000/µL ) A history Factor V deficiency Any coagulopathy medical condition require longterm anticoagulant therapy ( e.g. , warfarin ) transplantation ( lowdose aspirin treatment allow ) patient International Normalized Ratio ( INR ) &gt; 1.5 Severe coexist cardiac disease , characterize one condition : 1. recent myocardial infarction ( within past 6 month ) 2. evidence ischemia functional cardiac exam within last year 3. leave ventricular ejection fraction &lt; 30 % Persistent elevation liver function test ( LFTs ) time study entry ( e.g. , persistent SGOT ( AST ) , SGPT ( ALT ) , Alk Phos total bilirubin , value &gt; 1.5 time normal upper limit Symptomatic cholecystolithiasis Acute chronic pancreatitis Symptomatic peptic ulcer disease Severe unremitting diarrhea , vomit gastrointestinal disorder potentially interfere ability absorb oral medication Hyperlipidemia despite medical therapy ( fast LDL cholesterol &gt; 130 mg/dL , treat untreated ; and/or fast triglyceride &gt; 200 mg/dL ) Receiving treatment medical condition require chronic use systemic steroid , except use ≤ 5 mg prednisone daily , equivalent dose hydrocortisone , physiological replacement Use investigational agent within 4 week enrollment Administration live attenuate vaccine ( ) within 2 month enrollment Any medical condition , opinion investigator , interfere safe completion trial , chronic central neurologic disease Treatment antidiabetic medication insulin within 4 week enrollment A previous pancreas transplant , unless graft fail within first week due thrombosis , follow pancreatectomy transplant occur 6 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Insulin dependence</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Hypoglycemia unawareness</keyword>
	<keyword>Islet transplantation</keyword>
</DOC>